American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 5(65), 2021
DOI: 10.1128/aac.02420-20
Full text: Unavailable
Global infections by nontuberculous mycobacteria (NTM) are steadily rising. New drugs are needed to treat NTM infections, but the NTM drug pipeline remains poorly populated and focused on repurposing or reformulating approved antibiotics.